Vor Biopharma’s (VOR) “Market Outperform” Rating Reiterated at JMP Securities

JMP Securities restated their market outperform rating on shares of Vor Biopharma (NYSE:VOR) in a report released on Tuesday,Benzinga reports. They currently have a $12.00 price target on the stock.

Other analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $17.50 price objective on shares of Vor Biopharma in a research note on Tuesday. Robert W. Baird cut their price target on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Wedbush reiterated an “outperform” rating and set a $11.00 price objective on shares of Vor Biopharma in a research report on Monday. Finally, Barclays dropped their target price on Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating for the company in a report on Wednesday, August 14th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $11.36.

Vor Biopharma Price Performance

NYSE VOR opened at $0.98 on Tuesday. Vor Biopharma has a 1-year low of $0.63 and a 1-year high of $3.14. The company has a market cap of $67.17 million, a PE ratio of -0.59 and a beta of -0.37. The stock’s 50 day simple moving average is $0.80 and its 200-day simple moving average is $0.93.

Vor Biopharma (NYSE:VOR) last announced its earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.40). On average, equities research analysts anticipate that Vor Biopharma will post -1.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of Vor Biopharma by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock worth $4,297,000 after purchasing an additional 69,436 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Vor Biopharma by 48.0% during the second quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock worth $495,000 after buying an additional 160,642 shares during the period. Exchange Traded Concepts LLC increased its position in shares of Vor Biopharma by 40.8% during the third quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock valued at $116,000 after acquiring an additional 48,017 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Vor Biopharma by 51.4% during the second quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock valued at $79,000 after acquiring an additional 27,597 shares during the last quarter. Finally, Rosalind Advisors Inc. purchased a new stake in shares of Vor Biopharma in the 3rd quarter valued at approximately $54,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.